Phase II ATEZO-BRAIN: Updated Results With Atezolizumab + Carboplatin/Pemetrexed in Advanced Nonsquamous NSCLC With Untreated Brain Metastases

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Downloadable resource on the role of RET and NTRK aberrations in lung and thyroid cancer, including guidance on testing and review of the clinical data on RET and NTRK inhibitor therapy for these diseases, from Clinical Care Options (CCO)

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: November 14, 2022 Expired: November 13, 2023

Download this slideset for an overview of key data on immunotherapy in early-stage resectable and stage III unresectable NSCLC, from Clinical Care Options (CCO)

Zofia Piotrowska, MD, MHS Released: November 10, 2022